In this issue:
Dual CAR T cell therapy in R/R ALL
Long-term outcomes of tisagenlecleucel in R/R B-cell lymphomas
Venetoclax + dose-adjusted EPOCH-R in B-cell lymphoma
CEBPA-bZip mutations in AML
Donor-derived CD7 CAR T-cells for T-cell ALL
Long-term outcome of hyper-CVAD-R
Immunochemotherapy in PMBL
AlloHSCT in CML previously treated with 2nd generation TKIs
Ibrutinib in early-stage CLL
Response-adapted postinduction strategy in FL
Please login below to download this issue (PDF)